These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28774566)

  • 1. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
    Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
    Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
    Shearer JD; Henning L; Sanford DC; Li N; Skiadopoulos MH; Reece JJ; Ionin B; Savransky V
    Vaccine; 2021 Jan; 39(1):1-5. PubMed ID: 33199078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.
    Autumn Smiley M; Sanford DC; Triplett CA; Callahan D; Frolov V; Look J; Ruiz C; Reece JJ; Miles A; Ruiz E; Ionin B; Shearer JD; Savransky V
    Vaccine; 2019 Oct; 37(43):6356-6361. PubMed ID: 31530467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
    Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.
    Henning L; Anderson M; Triplett C; Smith T; Boyce K; Hendey L; Ridenour A; Eng J; Schaeufele D; Wilson E; Sabourin CL; Adams LE; Babas T; Parish L; Wolfe D
    Hum Vaccin Immunother; 2023 Dec; 19(3):2290345. PubMed ID: 38115181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
    Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
    Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
    Perry MR; Ionin B; Barnewall RE; Vassar ML; Reece JJ; Park S; Lemiale L; Skiadopoulos MH; Shearer JD; Savransky V
    Vaccine; 2020 Feb; 38(10):2307-2314. PubMed ID: 32029323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.
    Ionin B; Hopkins RJ; Pleune B; Sivko GS; Reid FM; Clement KH; Rudge TL; Stark GV; Innes A; Sari S; Guina T; Howard C; Smith J; Swoboda ML; Vert-Wong E; Johnson V; Nabors GS; Skiadopoulos MH
    Clin Vaccine Immunol; 2013 Jul; 20(7):1016-26. PubMed ID: 23658392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
    Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
    Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
    Stark GV; Sivko GS; VanRaden M; Schiffer J; Taylor KL; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6512-6517. PubMed ID: 27558619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
    Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
    Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats.
    Zmarowski A; Ballin JD; Sharits J; Carrico K; Novak J; Shearer J; Blauth B; Ionin B; Reece J; Savransky V
    Int J Toxicol; 2020 Jul; ():1091581820941412. PubMed ID: 32691648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.
    Rao VV; Godin CS; Lacy MJ; Inglefield JR; Park S; Blauth B; Reece JJ; Ionin B; Savransky V
    Int J Toxicol; 2021 Oct; 40(5):442-452. PubMed ID: 34281421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.
    Clement KH; Rudge TL; Mayfield HJ; Carlton LA; Hester A; Niemuth NA; Sabourin CL; Brys AM; Quinn CP
    Clin Vaccine Immunol; 2010 Nov; 17(11):1753-62. PubMed ID: 20739500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental and reproductive safety evaluation of AV7909 anthrax vaccine candidate in rats.
    Mylchreest E; Smiley MA; Ballin JD; Blauth B; Shearer J; Reece J; Ionin B; Savransky V
    Birth Defects Res; 2021 Jan; 113(1):32-42. PubMed ID: 33067910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.
    Wolfe DN; Espeland EM; Gao Y; Lu D; Blatner G; Amass K; Horwith G; Tong XM; Hopkins R; David GL; Jepson BM; King JC
    Vaccine; 2020 Nov; 38(50):7970-7976. PubMed ID: 33129609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
    Hopkins RJ; Howard C; Hunter-Stitt E; Kaptur PE; Pleune B; Muse D; Sheldon E; Davis M; Strout C; Vert-Wong K
    Vaccine; 2014 Apr; 32(19):2217-24. PubMed ID: 24613523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
    Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.